Kexing Biopharm and Changzhou Pharmaceutical Factory Enter into European Commercialization Agreement for Two Cardiovascular Drugs

Article source：Mar 23,2026View： 240

Recently, a strategic cooperation and exclusive licensing agreement for Ticagrelor Tablets and Rosuvastatin Calcium Tablets across multiple European countries was signed between Kexing Biopharm and Changzhou Pharmaceutical Factory Co., Ltd. (hereinafter referred to as "Changzhou Pharmaceutical Factory"), a subsidiary of Shanghai Pharmaceutical Group. Relying on Kexing Biopharm's extensive overseas commercialization network and Changzhou Pharmaceutical Factory's high-quality product R&D and manufacturing capabilities, both parties will work together to expand into the European market and allow Chinese-made cardiovascular drugs to benefit more patients.

Enriching European Product Portfolio and Deepening Presence in Key Market

Both products involved in the overseas cooperation have been approved in China and the United States and are undergoing registration applications in multiple European countries. The cooperation areas include markets such as Germany, Spain, the Netherlands, Italy, and France. Among them, Ticagrelor Tablets have been registered and approved in Italy and France, and Rosuvastatin Calcium Tablets have been approved in the Netherlands.

According to Business Research forecasts, the global ACS market size will be USD 10.07 billion in 2026 and will expand to USD 14.03 billion by 2035. The CAGR is predicted to be 3.7% from 2026 to 2035. According to MIDAS data, the global sales of Ticagrelor Tablets in 2024 were USD 2.03 billion, including USD 347 million in Europe.

And,according to persistence forecasts, the global statin market is expected to be USD 16.6 billion in 2025 and USD 20.6 billion by 2032, with a CAGR of 3.1%. This growth is mainly driven by the increase in cardiovascular disease rates, increased awareness of cholesterol management, and the need for effective lipid-lowering therapies as the population ages. According to MIDAS data, the global sales of Rosuvastatin Calcium Tablets reached USD 3.31 billion in 2024, including USD 706 million in Europe.

The European market is a key area that Kexing Biopharm has been working hard on in recent years. This overseas commercialization cooperation with Changzhou Pharmaceutical Factory for two products will help enrich the company's product portfolio for the European market and further enhance its market competitiveness.

Strong Alliance to Jointly Embark on a New Overseas Journey for Cardiovascular Drugs

On the day, Chen Ye, General Manager of Changzhou Pharmaceutical Factory, and Dr. Kelvin Shao, Vice General Manager of Kexing Biopharm, attended the signing ceremony and delivered speeches. Dr. Kelvin Shao said that the strategic cooperation with Changzhou Pharmaceutical Factory is a strategic move for Kexing Biopharm to deepen its presence in the European market and expand its global business. In the future, the company will give full play to its advantages in overseas registration and marketing channels, promote the rapid entry of two high-quality products into the European market, and realize mutual value creation and coordinated development between both parties.

Chen Ye, General Manager of Changzhou Pharmaceutical Factory, said that Changzhou Pharmaceutical Factory has been deeply involved in the pharmaceutical field for many years and has accumulated deep strength in drug product production and quality control. The Ticagrelor Tablets and Rosuvastatin Calcium Tablets launched in this cooperation are both cardiovascular drugs that are with clear clinical necessity, and their product quality and efficacy have been fully validated. He believes that through close cooperation between both parties, they can accelerate the overseas market penetration of the two products, enhance the global influence of Chinese-made pharmaceutical products, and achieve a dual improvement in social and economic benefits.

In recent years, Kexing Biopharm has continued to deepen its "innovation + internationalization" dual-wheel drive strategy. On the one hand, it has engaged in open cooperation and introduced a variety of high-quality products with high clinical value; on the other hand, it has increased R&D investment, focusing on areas such as oncology and autoimmune diseases to develop multiple global innovative drug pipelines, and is committed to becoming an innovative international biopharmaceutical company to serve patients around the world.